Mohsin Saeed
All Posts
-
The Best Healthcare Bet
By Mohsin Saeed - June 18, 2013 | Tickers: ABT, BMY, GILD
Gilead (NASDAQ: GILD) has been one of the most prolific investments in the healthcare sector. The company value has almost doubled in the last few years, and it continues to appreciate thanks to its stellar R&D. Gilead dominates the Hepatitis C Virus (HCV) treatment market, and the upcoming priority review of sofosbuvir can cement its HCV domination for years to come. It faces tough competition from Bristol Myers Squibb more »
-
50% Upside on This Semiconductor Giant
By Mohsin Saeed - June 17, 2013 | Tickers: AMD, INTC, MSFT
The PC semiconductor industry has suffered due to declining PC shipments. Industry giants such as Intel (NASDAQ: INTC) and Advanced Micro Devices (NYSE: AMD) have struggled to cope with the rising trend of handhelds. This decline has forced the leading PC industry players to diversify or develop more energy efficient chips, to target handheld devices.
Late last year, AMD was trading at under $2 due to continuous losses and more »
-
Huge Upside on Pipeline Strength
By Mohsin Saeed - June 17, 2013 | Tickers: AMGN, GILD, PFE
Amgen (NASDAQ: AMGN) is the world’s largest independent biotechnology company. It has managed to produce a string of successful drugs and still has one of the richest pipelines in the entire healthcare sector. The shares have appreciated significantly during the last 52 weeks, but the strong pipeline demands even better valuations. A number of catalysts are approach which can significantly improve the company’s valuations and reinforce its long more »
-
Lack of Innovation Could Sink Technology's Titanic
By Mohsin Saeed - June 17, 2013 | Tickers: AAPL, GOOG, P
The market still expects Apple (NASDAQ: AAPL) to blow their minds at each and every product launch. In the recent past, the company has not lived up to these high expectations. There were high hopes from Apple’s annual Worldwide Developers Conference. The street had been speculating on the launch of a cheaper iPhone, smartwatch, TV, payment solutions etc. The biggest product news from the WDC was the launch of more »
-
3 Dividend Plays You Can't Miss
By Mohsin Saeed - June 12, 2013 | Tickers: FTE, PTNR, VIP
Editor's Note: France Telecom cut their dividend, this article has been amended to reflect this.
The Fed is trying to revive the economy by reducing rates and encouraging consumer spending. The effectiveness of this methodology is debatable but the reduction has definitely increased the demand for dividend stocks. High dividend yields are not common in the technology sector because companies are more concerned about R&D and growth. The more »
-
A Winning Biotechnology Bet
By Mohsin Saeed - June 10, 2013 | Tickers: AMRN, AZN, OMTH
Amarin (NASDAQ: AMRN) has recently launched its primary product candidate Vascepa into the market. The drug is an omega-3 fatty acid eicosapentaenoic which has been approved by the FDA for treatment of high levels of TGT.
A market launch of Vascepa was never part of the plan, investors expected Amarin to cut a multi-billion acquisition deal instead, so everyone could go back home with pockets full of cash.
However, the more »
-
Two Stocks to Buy on M&A
By Mohsin Saeed - June 10, 2013 | Tickers: CLWR, DISH, S
The telecommunication industry is going through a major consolidation. Dish Network (NASDAQ: DISH) and Japanese’s Softbank are both trying to acquire Sprint Nextel (NYSE: S). Dish is in the process of finalizing its offer, but the board of Sprint has already invited shareholders to vote for the Softbank bid on June 12.
To complicate matters more, Dish is also competing with Sprint to acquire Clearwire . (NASDAQ: CLWR) Sprint is more »
-
A Good Short Candidate
By Mohsin Saeed - June 6, 2013 | Tickers: AAPL, P, SIRI
It is extremely difficult to assess the potential of companies relying on online display advertisement. The access to a global clientele increases the variation of estimates and in turn leads to varying assumptions about their true potential or value. The most successful online display advertisement businesses usually rely on content generated by users e.g. Facebook, YouTube, Yahoo, and Twitter etc. The high cost of content makes it pretty tough more »
-
2 Stocks to Buy, 1 to Hold
By Mohsin Saeed - June 6, 2013 | Tickers: HNSN, OPK, PACB
Insider buying is widely considered a positive indicator for any company. This holds truer for biotechnology companies because valuations are linked to pipeline candidates. The insiders have the most information about the progress of these candidates along with other vital information about the company.
However, insider buying can also mislead investors into making investments at inopportune moments. Therefore, it is important to view insiders buys in combination with other fundamental more »
-
2 Drugs With Acquisition Potential
By Mohsin Saeed - June 5, 2013 | Tickers: AZN, GALE, ONCY
Big pharmaceutical players, known as Big Pharma, depend on patents to fend of generic threats to their blockbuster drugs. So when a patent expires, cheaper generic products flood the market. The sales of the premium drug take a nose dive once similar compounds are available at cheaper rates.
Therefore, it is imperative for big-pharmaceutical players to continue the hunt for new candidates. In this lies the enormous potential of small more »
-
Can This Smartphone Giant Surprise?
By Mohsin Saeed - June 5, 2013 | Tickers: AAPL, BBRY, MSFT
Apple (NASDAQ: AAPL) has redefined the smartphone experience with its iOS and iPhone. Only Google and Samsung have shown the ability to adapt and adopt this revolution with their Android devices. Due to this rise of iOS and Android, BlackBerry (NASDAQ: BBRY) has seen falling sales of its BB devices and declining service revenues. The company is trying once again to become relevant with its exciting new BB10 OS and more »
-
3 High Dividend Healthcare Stocks
By Mohsin Saeed - June 4, 2013 | Tickers: AZN, VIVO, SEM
The U.S. government has been consistently cutting rates for the last few years. The aim of this exercise is to jump start the sluggish U.S. economy. While rate cuts contribute towards economic growth, they make life difficult for fixed income investors. A lot of these investors have started investing in dividend stocks. This is the very reason that demand for high dividend stocks has greatly increased.
The healthcare more »
-
Is This Comeback for Real?
By Mohsin Saeed - May 28, 2013 | Tickers: CSCO, HPQ, IBM
Hewlett-Packard (NYSE: HPQ) has been in the news a lot recently. Once a pioneer in PC and printing technology, the company has fallen on hard times. But despite major setbacks, the company's stock has appreciated by a phenomenal 95% in the last 6 months. Let’s examine whether fundamental or industry catalysts can justify this rally.
Fundamentals
HP's management has written off $8.8 billion of the $11 more »
-
Why This Obesity Drug Is the Sector's Best Bet
By Mohsin Saeed - May 24, 2013 | Tickers: ARNA, OREX, VVUS
Editor's Note: The original article incorrectly stated Schedule IV drugs are the second-most-restrictive. This version has been corrected and Motley Fool apologizes for the oversight.
The obesity drug space is becoming increasingly complex and hard to predict. After months of waiting patiently, Arena Pharmaceuticals (NASDAQ: ARNA) finally got a DEA schedule for its star drug Belviq in May, which could clear up the primary obstacle to Belviq’s availability more »
-
2 Biotechs to Avoid, 1 to Buy
By Mohsin Saeed - May 23, 2013 | Tickers: MNKD, OPTR, PDLI
Keeping a close eye on two particular classes of investors can tell you a lot about how stocks might move in the future. Institutional investors have resources at their disposal that ordinary investors lack. Moreover, they own such large stakes in their investments that their moves can materially influence a stock's price.
Meanwhile, important information about upcoming catalysts is more readily available to the insiders, compared to the rest more »
-
Which Advertisement Giant Will Win in Mobile?
By Mohsin Saeed - May 23, 2013 | Tickers: FB, GOOG, YHOO
Internet ads represent one of the fastest-growing industries in the entire technology sector. The business has changed radically in the last few years, showing average revenue growth of around 15%. This fast growth is due to the increased usage of handheld devices. As users spend more time online with their smartphones and tablets, leading online advertisers Facebook (NASDAQ: FB), Google (NASDAQ: GOOG) and Yahoo! (NASDAQ: YHOO) must now find new more »
-
20% Upside on This Technology Powerhouse
By Mohsin Saeed - May 18, 2013 | Tickers: CSCO, IBM, JNPR
Against all odds, Cisco (NASDAQ: CSCO) has managed to beat estimates yet again. The company reported another stellar quarter, showing further improvements in its enterprise business. The quarter also makes the case for long term investment in the company due to a smooth execution of the company's new strategic plan and stable performance despite a poor industry outlook. The analysis shows that the company has a 20% upside on more »
-
Dell: Time to Jump Ship
By Mohsin Saeed - May 18, 2013 | Tickers: DELL, LNVGY.PK, MSFT
The PC industry has suffered from the rise in tablet and smartphone demand. In the last couple of years, the handhelds have emerged as the future to all computing which has severely impacted the PC sales. In the last few quarters, major OEMs (Original Equipment Manufacturers) like Dell (NASDAQ: DELL) and HP have suffered a steady decline in sales.
Whenever any industry starts declining, investors usually witness considerable restructuring activity more »
-
2 Stocks Moving on Earnings
By Mohsin Saeed - May 7, 2013
We are already in the middle of the earnings season with some major technology earnings already out. This earnings season has been particularly kind to the US Internet advertisement industry. Most companies have met or exceeded the earnings estimates. This shows that the growth in handheld devices continues to drive this entire space and shatter analyst estimates.
Most major players have already reported their results but AOL (NYSE: AOL) and more »
-
Improving Prospects of This Obesity Bet
By Mohsin Saeed - May 6, 2013 | Tickers: ARNA, OREX, VVUS
VIVUS' (NASDAQ: VVUS) Qsymia has not received the unconditional consumer love that investors were hoping. The initial sales data has been pretty slim, which has forced the company to lower prices more than once. VIVUS is trying to gain some sales momentum before its primary competitor, Belviq, from Arena Pharmaceuticals (NASDAQ: ARNA) hits stores.
Orexigen Therapeutics (NASDAQ: OREX) is still trying to get the FDA to sign off on Contrave more »
- Page 1 of 9
- »